Coherus pays out $32M for exclusive US commercialization rights to Eylea biosimilar

cafead

Administrator
Staff member
  • cafead   Jan 10, 2023 at 06:52: PM
via Coherus BioSciences is adding to its pipeline, this time grabbing commercialization rights for a biosimilar of one of the largest ophthalmology drugs on the market.

article source
 

<